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Abstract
Background. Prevention of cardiovascular diseases is
essential in chronic haemodialysis patients. Recently,
low-dose spironolactone has been shown to decrease
cardiovascular mortality in patients with severe heart
failure. However, since haemodialysis patients are
prone to hyperkalaemia, a known side effect of
spironolactone, this treatment is not used in this
population. We performed a study to assess whether
low-dose spironolactone (3 25mg/week) could be
administered without inducing hyperkalaemia in
haemodialysis patients.
Methods. The study design included a 2-week baseline
period, followed by a 4-week treatment period in which
doses of spironolactone were started at 12.5mg three
times/week for 2 weeks, then increased to 25mg three
times/week, and followed by a 2-week wash-out period.
Fourteen patients receiving low-dose spironolactone
after each dialysis were compared with 21 haemodial-
ysis patients (control group).
Results. Low-dose spironolactone did not change
mean serum potassium (4.9±0.7 vs 4.9±0.3mmol/l:
control). The mean plasma canrenone level induced by
administration of spironolactone 25mg three times/
week in the 14 treated patients was 13±5.3 ng/ml.
Serum aldosterone was not signiﬁcantly modiﬁed by
the administration of spironolactone in these patients
[before, median 0.35; interquartile range (IQR) 0.11–
2.83 nmol/l vs after, median 0.22; IQR 0.12–0.60 nmol/l,
NS]. Dietary potassium intake and the use of ion-
exchange resin, angiotensin-converting enzyme inhibi-
tors and -blockers were similar for the two groups
throughout the study.
Conclusion. This non-randomized and non-blinded
study shows that administration of 25mg spironolac-
tone thrice weekly is not associated with an increased
frequency of hyperkalaemia in haemodialysis patients
when they are carefully monitored. More studies are
required, however, before concluding that spironolac-
tone administration is safe in the chronic haemodial-
ysis population.
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Introduction
Cardiovascular disorders are common in chronic
haemodialysis patients, and account for 50% of
the deaths in this population, which is affected by a
mortality rate 10–20 times higher than in the general
population [1–4]. New therapeutic strategies are
needed to decrease this rate of cardiovascular deaths
among haemodialysis patients. The RALES study
showed a dramatic reduction of morbidity and
mortality in patients suffering from severe heart
failure, with inhibition of aldosterone by low-dose
spironolactone treatment (25mg/day) associated with
maximal therapy [5]. Aldosterone is a potent mediator
of myocardial and vascular ﬁbrosis, and reduced levels
of serum markers of cardiac ﬁbrosis were measured
after treatment with low-dose spironolactone [6]. Aldo-
sterone is also a potent kaliuretic hormone but, despite
concomitant treatment with angiotensin-converting
enzyme inhibitors (ACEIs) in 94% of patients, use of
low-dose spironolactone did not increase the preva-
lence of hyperkalaemia [5]. However, no patients with
severe chronic renal failure were enrolled in this study.
Recently, life-threatening hyperkalaemia during com-
bined therapy with ACEIs and spironolactone has
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been reported in patients with moderate chronic renal
impairment [7]. Though renin–angiotensin system
blockade currently is recommended in haemodialysis
patients, it has been reported to be independently
associated with an increased risk of developing
hyperkalaemia [8]. Serious hyperkalaemia is reported
to occur in 10% of haemodialysis patients and to be
responsible for 3–5% of deaths in dialysis [9].
However, the risk of worsening hyperkalaemia with
low-dose spironolactone has not been estimated so far
in such patients. In chronic renal failure patients, the
role of aldosterone in extrarenal homeostasis of
potassium (intestinal and cellular) is not well deli-
neated. Patients with chronic renal failure tend to have
an increased intestinal excretion of potassium [10].
Anephric haemodialysis patients treated with high
doses of spironolactone (300mg/day) had higher
serum potassium levels after an oral potassium chal-
lenge without modifying the fecal excretion of potas-
sium [11]. This suggests a role for aldosterone in the
cellular uptake of potassium in these patients. With
modest dietary potassium intake, administration of
spironolactone seemed to inﬂuence serum potassium
only transiently [11].
Spironolactone has a bioavailability of 90% and is
metabolized rapidly by the liver. Its active metabolites,
canrenone and 7 methylspironolactone, have a long
half-life (15–20 h) and 95% plasma protein binding
[12]. Both metabolites are partially eliminated by the
kidney (50%), and spironolactone dosage must be
decreased in end-stage renal failure (ESRF). We
hypothesized that 25mg three times weekly in haemo-
dialysis patients will be equivalent to the low-dose
spironolactone regimen used (25mg/day) in patients
with normal or slightly impaired renal function [5] and
may be administered without increased risk of severe
hyperkalaemia.
Subjects and methods
Patients and design of the study
Thirty-ﬁve patients on chronic haemodialysis treatment
(three sessions a week) were enrolled in a non-randomized
and non-blinded study. Fourteen patients agreed to receive
spironolactone and were included in the spironolactone
group. Of these, 12 were anuric or had a residual urine
output of <300ml/day. Twenty-one haemodialysis patients
declined to receive spironolactone but accepted to be enrolled
in the control group. Besides our routine procedures and
controls, the protocol of the study included a dietary survey
and blood potassium measurements before each haemodial-
ysis session during the study period. The ethics committee of
the Department of Medicine approved the study.
Design of the study
The study design included a 2-week baseline period, followed
by a 4-week treatment period in which doses of spirono-
lactone (Aldactone, Pharmacia AG, Switzerland) were
started at 12.5mg three times/week taken just after the
haemodialysis session for 2 weeks, then increased to 25mg
three times/week, and followed by a 2-week wash-out period.
Throughout the study, measurements of serum potassium
were performed before each dialysis session in both groups.
All patients had a haemodialysis solution with 3mmol/l of
potassium, which is part of our routine procedure. Serum
aldosterone levels of patients treated with spironolactone
were determined after 2 weeks (run-in) and 6 weeks
(spironolactone 25mg three times/week). As spironolactone
was administered three times a week and has a much
shorter half-life than canrenone, its main metabolite, we
measured the plasma level of canrenone after 6 weeks in the
spironolactone-treated patients. This measurement was done
before the dialysis session and the next administration of
spironolactone. Prior to the observation period, dietary
advice was provided to all haemodialysis patients, and a
basic dietary survey was answered at each dialysis session
throughout the study. Daily dietary potassium intake was
then estimated by dietitians unaware of patient’ group
attribution. Interdialytic dietary potassium intake was
ranked from 5 to 1 (high, always >2700mg/day; high–
medium, not constantly >2700mg/day; medium, always
2000–2700mg/day, medium–low, between 2700 and <2000
mg/day; and low, always <2500mg/day). ECGs were
performed on a weekly basis in the spironolactone-treated
group.
Serum aldosterone measurements
Blood was collected from supine patients and serum was
frozen at –20C. Before assay, samples were slowly thawed at
room temperature and aldosterone was measured by direct
solid-phase radioimmunoassay, using a commercially avail-
able kit (Diagnostic Products Corporation, Los Angeles,
CA), according to the supplier’s instructions. The intra-assay
precision (CV) was between 2.7 and 8.3% and the interassay
precision between 3.6 and 10.4%, with a limit of detection of
0.04 nmol/l. Cross-reactivity of the antibody with spirono-
lactone was estimated to be 0.06%. Expected values for
normal supine patients are 0.03–0.44 nmol/l [13].
Plasma canrenone measurements
Frozen plasma samples were analysed by reversed-phase
high-performance liquid chromatography (HPLC) after solid
phase extraction by a bioanalytical company (Biokinet
GmbH, Vienna, Austria). HPLC was performed on a reverse
phase C18 column with an eluent of methanol/acronitrile/
water and UV detection at 280 nm [14].
Statistical analysis
We compared serum potassium in the spironolactone
and control groups, adjusting for study period, and taking
into account correlations among repeated observations in
the same patient by means of generalized estimating
equations. All tests of statistical signiﬁcance for continuous
(Student’s t-test) and categorical (2 test) were two-tailed.
Non-parametric tests were used for non-normally distributed
data. Calculations were performed using SPSS, version
10.0 (Chicago, IL) and STATA, version 7, Stata Corp
(College Station, TX).
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Results
Patient characteristics
Baseline demographic and clinical characteristics of
our patients are listed in Table 1 and did not differ
between the two groups (spironolactone and control)
except for a trend toward a longer duration of renal
replacement therapy for the spironolactone group.
In particular, use of ion-exchange resins was similar in
both groups, as well as the use of medications known
to have hyperkalaemic properties.
Serum potassium, dietary potassium and
aldosterone levels
Serum potassium did not change in the spironolactone
group during the whole study period (Figure 1). Mean
baseline, 12.5mg period, 25mg period and wash-out
period serum potassium levels were respectively
5±0.4, 4.9±0.4, 4.9±0.3 and 4.9±0.4mmol/l in
the spironolactone group, and 4.8±0.8, 4.9±0.7,
4.9±0.7 and 4.6±0.7mmol/l in the control group. In
a multivariate analysis adjusted for baseline kalaemia,
spironolactone treatment was associated with a mod-
est reduction in serum potassium (–0.2mmol/ml,
P¼ 0.016). Dietary potassium intake was (on a scale
from 5 to 1) similar for the two groups throughout the
study [25mg spironolactone period, 2.6±1.2 (spiro-
nolactone) vs 2.2±0.9 (control), NS] and did not
correlate with serum potassium. The mean plasma
canrenone level in the 14 patients treated with spiro-
nolactone 25mg three times/week was 13±5.3 ng/ml.
Use of ion-exchange resin was comparable between
the two groups during the study period. Basal serum
aldosterone levels were not signiﬁcantly modiﬁed by the
administration of spironolactone in the 14 treated
patients [before, median 0.35 nmol/l; interquartile range
(IQR) 0.11–2.83 nmol/l vs after, median 0.22 nmol/l;
IQR 0.12–0.60 nmol/l, NS]. There was no correlation
between serum aldosterone and potassium levels.
Electrocardiograms
The weekly ECGs were analysed by two cardiologists
unaware of the presence of spironolactone treatment;
no signs of hyperkalaemia were found.
Discussion
In this non-blinded, non-randomized study, 25mg of
spironolactone administered thrice weekly to haemo-
dialysis patients did not increase serum potassium.
Fig. 1. Serum potassium in 14 haemodialysed patients included in the study (black dots) and in 21 controls who declined the study (grey dots).
Lines represent non-parametric regression lines. Patients in the spironolactone group received no treatment during weeks 1–2 (run-in) and 7–8
(wash-out), 12.5mg after each haemodialysis session during weeks 3–4, and 25mg during weeks 5–6. Control patients received no
spironolactone throughout.
Table 1. Characteristics of study patients
Spironolactone Control group
group (n¼ 14) (n¼ 21)
Age (years) 54±14 59±17 NS
Renal replacement therapy 67 (8–183) 24 (11–100) NS
(months) (medianþ IQR)
Diabetes 2 5 NS
Residual renal function 2 6 NS
ACEIs/ARBs 8 11 NS
-Blockers 5 6 NS
HCO3 (mmol/l) 22.9±1.9 23.5±2.8 NS
Kt/V 1.27 (0.2) 1.22 (0.22) NS
Ion-exchange resin 8 8 NS
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These results demonstrate that the cautious adminis-
tration of spironolactone should not be contraindi-
cated in this population known to have a dramatic
increase in cardiovascular mortality.
This study does have some limitations, however.
First, the dose used in this study is below the average
dose used in the RALES study. Based on the
metabolism of spironolactone, we have estimated
that similar plasma drug levels in haemodialysis
patients should be obtained with 25mg given three
times a week. However, the demonstration of a
pharmacological effect using markers such as those
used in the RALES dose-ﬁnding study (sodium
retention test, N-terminal pro-ANF and PRA levels)
was not possible in this study because of the renal
failure. As no spironolactone or canrenone determina-
tion was performed in the RALES study, we do not
know whether low-dose spironolactone three times/
week in haemodialysis patients provides similar plasma
levels as those reached after daily administration.
Mean plasma canrenone level, determined at 48 h in
our study group, was 50% lower than the mean
plasma canrenone level obtained at 24 h in normal
volunteers receiving a conventional dose of 50mg
spironolactone daily over 5 days [15]. Therefore, we
estimate that 25mg of spironolactone three times/week
in haemodialysis patients is equivalent to the average
dose used in the RALES study.
Another important limitation is the design of the
study. This was a non-blinded, non-randomized study.
To include only patients who accepted to receive
spironolactone may have introduced some bias favour-
ing a tighter potassium control. To examine this
possibility, we enrolled all the patients who declined
to receive spironolactone in the control group. The
patients included in the study were closely monitored
(serum potassium dosage at each dialysis), and most of
them were compliant with the low potassium diet. Our
dietary survey, however, did not detect major differ-
ences in dietary potassium intake between the two
groups or in the use of exchange resins. It is unlikely
that the participating subjects deliberately restricted
their potassium intake. However, we cannot rule out
the possibility that low-dose spironolactone would
aggravate hyperkalaemia in the case of acutely incre-
ased dietary potassium intake, exertional hyperkalae-
mia, hyperglycaemia or digoxin toxicity. Similarly,
more than half of our patients were also treated with
ACEIs or angiotensin receptor blockers (ARBs). The
low number of patients included in the study prevents
us from asserting that low-dose spironolactone admin-
istration in haemodialysis patients treated concomi-
tantly with ACEIs or ARBs is completely safe. In
addition, most of the patients in the spironolactone-
treated group had no residual renal function, and
we cannot extrapolate our results to haemodialysis
patients with residual diuresis, where renal potassium
excretion, albeit reduced, is still present. Finally, due to
its molecular weight and its high protein binding [12],
plasma levels of spironolactone and its active metab-
olites should be unchanged by haemodialysis, but more
data on the pharmacokinetics of these compounds
during haemodialysis are necessary. Hyperkalaemia
induces the activation of both renal and extrarenal
homeostatic mechanisms to decrease serum potassium.
Long-term extrarenal potassium homeostasis is regu-
lated principally by gastrointestinal excretion in
haemodialysis patients. However, low-dose spirono-
lactone does not seem to interfere signiﬁcantly with
colonic adaptation to hyperkalaemia in haemodialysis
patients. Our results are in agreement with a previous
study investigating the action of aldosterone in
anephric haemodialysis patients, where seven patients
were challenged with 300mg of oral spironolactone
daily vs no medication during 3 days. Spironolactone
was found to induce a small and transient rise in
potassium levels after an acute potassium load.
However, no persistent hyperkalaemia and no change
in intestinal potassium excretion were demonstrated
[11]. Recently, low-dose spironolactone (25mg) admin-
istered every day for 10 months was not found to
elevate serum potassium above 5.5mmol/l in a patient
treated by peritoneal dialysis and suffering from heart
failure [16]. This treatment resulted in a signiﬁcant
improvement of his ejection fraction (from 32 to 46%).
Plasma aldosterone levels become elevated with
advanced renal failure and participate in the adap-
tative mechanisms of chronic renal failure. Haemodial-
ysis patients are characterized by high basal levels of
plasma aldosterone [13] and, recently, plasma aldo-
sterone concentrations were shown to be related to left
ventricular hypertrophy in non-diabetic ESRF patients
[15]. In our patients, mean basal serum aldosterone
levels were not high, but a wide range of values was
observed which might be due to concomitant renin–
angiotensin system blockade. Similarly, no signiﬁcant
change in serum aldosterone levels was demonstrated
in the spironolactone-treated group, making it unlikely
that low doses of spironolactone enhance aldosterone
secretion.
We do not know whether 25mg of spironolactone
administered three times weekly would be effective in
decreasing cardiovascular mortality in these patients,
and it is unreasonable to expect cardiovascular data in
a single centre short-term trial. Regarding the high
cardiovascular mortality in these patients, the results
of this study are encouraging because they open up
the possibility of a treatment which has demonstrated
its efﬁcacity in patients with normal renal function.
However, because of several limitations (non-
randomized and non-blinded, administration of kayex-
elate, tight monitoring of serum potassium levels), this
study has to be considered as a pilot study and we
cannot conclude that spironolactone administration
(25mg three times/week) will be equally safe under
other conditions. Indeed, more clinical trials to study
thoroughly the pharmacokinetics of low-dose spirono-
lactone during haemodialysis and to assess the safety
of spironolactone in a larger haemodialysed popula-
tion should be performed before drawning any con-
clusions regarding the safety of spironolactone in this
population.
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